Evidence map›Paper›PMID 26868283›Full record

ArticleAmerican journal of preventive medicine2016

Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S.

Kenneth J Smith, Jonathan M Raviotta, Jay V DePasse, Shawn T Brown, Eunha Shim, Mary Patricia Nowalk, Richard K Zimmerman

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of preventive medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Observational
  6. Potential Consequences of Not Using Live Attenuated Influenza Vaccine.American journal of preventive medicine · 2017
    Article
  7. Cost-Effectiveness of Dengue Vaccination Programs in Brazil.The American journal of tropical medicine and hygiene · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Kenneth J SmithUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Electronic address: smithkj2@upmc.edu.
Jonathan M RaviottaUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Jay V DePassePittsburgh Supercomputing Center, Carnegie Mellon University, Pittsburgh, Pennsylvania.
Shawn T BrownPittsburgh Supercomputing Center, Carnegie Mellon University, Pittsburgh, Pennsylvania.
Eunha ShimDepartment of Mathematics, Soongsil University, Seoul, South Korea; Department of Mathematics, University of Tulsa, Tulsa, Oklahoma.
Mary Patricia NowalkUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Richard K ZimmermanUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
University of Pittsburgh · USCarnegie Mellon University · USPittsburgh Supercomputing Center · USSoongsil University · KR

Funding

Future of influenza vaccine strategies given interference and choiceR01GM111121 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SMITH, KENNETH J, ZIMMERMAN, RICHARD K · 2014 to 2017
$1.6M
NIGMS NIH HHS R01 GM111121NIGMS NIH HHS R01GM111121
6 · The paper itself

Abstract

introductionPrior evidence found live attenuated influenza vaccine (LAIV) more effective than inactivated influenza vaccine (IIV) in children aged 2-8 years, leading CDC in 2014 to prefer LAIV use in this group. However, since 2013, LAIV has not proven superior, leading CDC in 2015 to rescind their LAIV preference statement. Here, the cost effectiveness of preferred LAIV use compared with IIV in children aged 2-8 years is estimated.

methodsA Markov model estimated vaccination strategy cost effectiveness in terms of cost per quality-adjusted life-year gained. Base case assumptions were equal vaccine uptake; IIV use when LAIV was not indicated (in 11.7% of the cohort); and no indirect vaccination effects. Sensitivity analyses included estimates of indirect effects from both equation- and agent-based models. Analyses were performed in 2014-2015.

resultsUsing prior effectiveness data in children aged 2-8 years (LAIV=83%, IIV=64%), preferred LAIV use was less costly and more effective than IIV (dominant), with results sensitive only to LAIV and IIV effectiveness variation. Using 2014-2015 U.S. effectiveness data (LAIV=0%, IIV=15%), IIV was dominant. In two-way sensitivity analyses, LAIV use was cost saving over the entire range of IIV effectiveness (0%-81%) when absolute LAIV effectiveness was >7.1% higher than IIV, but never cost saving when absolute LAIV effectiveness was <3.5% higher than IIV.

conclusionsResults support CDC's decision to no longer prefer LAIV use and provide guidance on effectiveness differences between influenza vaccines that might lead to preferential LAIV recommendation for children aged 2-8 years.

Indexed as

Centers for Disease Control and Prevention, U.S.ChildChild, PreschoolCost-Benefit AnalysisHumansInfluenza, HumanInfluenza VaccinesMarkov ChainsQuality-Adjusted Life YearsUnited StatesVaccinationVaccines, InactivatedVaccines, Live, UnattenuatedInfluenza VaccinesVaccines, InactivatedVaccines, Live, Unattenuated

Identifiers

PMID26868283
PMCPMC4841730
OpenAlexW2262754969

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.